T0	Interventions 72 95	hormonal contraceptives
T1	Interventions 193 234	hormonal contraceptive vaginal ring (CVR)
T2	Interventions 250 289	nonandrogenic progestin Nestorone (NES)
T3	Interventions 294 311	ethinyl estradiol
T4	Interventions 953 1106	randomized to three cycles of treatment with a CVR delivering NES/EE (150/15 microg/day) or a combined OC providing LNG and EE (150/30 microg per tablet)
T5	Interventions 1108 1198	Each cycle consisted of 21 days of active treatment, followed by 7 days without treatment.
T6	Interventions 1269 1645	blood samples were obtained for determinations of plasma concentrations of angiotensinogen, an estrogen-sensitive hepatic protein, and serum concentrations of sex hormone-binding globulin (SHBG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG) and estrogen- and androgen-sensitive proteins.
T7	Interventions 3328 3338	NES/EE CVR
T8	Interventions 3347 3356	LNG/EE OC